Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c69221) has announced the addition of Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices to their offering. Despite significant advances in prevention and treatment, cardiovascular disease remains the leading cause of death in economically advanced countries. The developing world has also begun to experience a disconcerting dis·con·cert tr.v. dis·con·cert·ed, dis·con·cert·ing, dis·con·certs 1. To upset the self-possession of; ruffle. See Synonyms at embarrass. 2. growth in prevalence, where the insurgence in·sur·gence n. The action or an instance of rebellion; an insurrection. insurgency, insurgence 1. the state or condition of being in revolt or insurrection. 2. an uprising. of CVD CVD Cardiovascular disease, see there has exacerbated the risk factors associated with indigenous communicable diseases. Keeping pace with epidemiological change in both the developed and developing world constitutes the overriding challenge for industrial players, and involves successfully integrating into localised healthcare systems and reimbursement structures, in addition to remaining aligned with product demand. In the medical device, pharmaceutical and biotechnology industries, this challenge is being met with a focus on products that reduce adverse effects, improve patient outcomes and extend the range of formulations for existing indications. 'Innovations in Cardiovascular Disease Management' is a new report that will examine the major developments shaping the future of the cardiovascular industry. This report will analyse the future potential of new and emerging products from the medical device, pharmaceutical and biotechnology sectors, and measure their likely impact upon the existing market. The extent to which these products can stimulate the growth and development of the future market will also be assessed. Use this report to evaluate the potential of new and emerging products in the treatment of cardiovascular diseases, assess the strength of competitor pipelines and identify future market opportunities. Some key findings from this report: -The worldwide market for coronary stents was valued at $6.18bn in 2006, and with a projected CAGR CAGR See: Compound Annual Growth Rate of 11.6%, is expected to be valued at $13.34bn by the year 2013. Estimates show that 95.9% of all PCI (1) (Payment Card Industry) See PCI DSS. (2) (Peripheral Component Interconnect) The most widely used I/O bus (peripheral bus). procedures in 2006 included a BMS or DES coronary stent. -The coronary stent market is likely to be revolutionised by novel advancements including Absorbable Metal Stent (AMS AMS - Andrew Message System ) Technologies, novel coating technologies, gene therapy technologies, Endothelial Progenitor Cells, nanotechnologies, drug-eluting coronary stents, novel Estradiol containing drug-eluting stents and regenerative stents. -Novartis' Rasilez (aliskiren) and Exforge (valsartan/amlodipine) are two major anti-hyperintensives set be launched in 2007. Novartis' Tektuma was US FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved in early 2007, with EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. approval for the treatment of high blood pressure also expected later this year. -In April 2007, Abbot Laboratories submitted an NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any to the FDA for a fixed dose combination A fixed dose combination (FDC) is a formulation of two or more active ingredients combined in a single dosage form available in certain fixed doses. Fixed dose combination drug products may improve medication compliance by reducing the pill burden of patients. Niaspan (extended release niacin) and Simvastin, whilst hoping to launch Simcor at the start of 2008. -A total of 126 New Chemical Entities (NCE's) are currently in preclinical trials, including 51 in Phase I and 122 in Phase II. Top five reasons to order your copy today: -Identify the new and impending im·pend intr.v. im·pend·ed, im·pend·ing, im·pends 1. To be about to occur: Her retirement is impending. 2. medical device technologies that are set to have a major impact upon the coronary stent market. -Discover the emerging cardiovascular drugs with greatest potential, and learn of their anticipated launch dates and markets of entry. -Track the development of bioabsorbable coronary stents and evaluate their potential influence upon the coronary stent market. -Assess the early stage development and current status of new and innovative embolic protection devices. -Analyse the best performing Minimally Invasive Cardiac Surgery minimally invasive cardiac surgery Interventional cardiology Any of a number of techniques–MIDCAB, off-pump coronary-artery bypass, minimally invasive valve surgery, port-access coronary surgery, and port-access valve surgery–increasingly being used to (MICS) technologies, and understand their impact upon the cardiac surgery and percutaneous coronary intervention Percutaneous coronary intervention (PCI), commonly known as coronary angioplasty or simply angioplasty, is a therapeutic procedure to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. (PCI) markets. Key issues examined in this report... -The world's number one killer. CVD remains the leading cause of death in the US, accounting for 53% of all deaths. Rising mortality rates in Central and Eastern Europe The term "Central and Eastern Europe" came into wide spread use, replacing "Eastern bloc", to describe former Communist countries in Europe, after the collapse of the Iron Curtain in 1989/90. are prompting increased concern. -Concerns over drug-eluting stents. Clinicians are harbouring major concerns over numerous complications associated with drug eluting stents. Most notably, these include the onset of late-developing stent thrombosis, allergic inflammatory reactions and non-compliance. -Significant global PCI procedural rates. In 2005/06, Germany had the world's highest procedural rate with 225,000 PCI's (2,765pmp), compared to China's 95,912 (73pmp) and India's 42,123 (41pmp). -Discontinuation of Pfizer's Torcetrapib. The failure of the experimental cholestorol drug has cast doubt over rival products from within the CETP CETP Cholesteryl Ester Transfer Protein CETP Certified Employee Training Program CETP Common Effluent Treatment Plant CETP China Energy Technology Program CETP Centre de Recherches en Physique de l'Environment Terrestre et Planetaire (French) inhibitor pipeline, although Roche Holding AG are continuing the development of R1658. It has however created a major opportunity for the recently approved Vytorin (Inegy) and Zetia. -Discontinuation of Astra-Zeneca's Exanta. A substantial blow to the anti-thrombotics pipeline, Exanta was expected to challenge Warfarin. Your questions answered... -Which cardiovascular disease areas will experience the most significant expansions in prevalence over the short, medium and long-term. ? -What are the indications for percutaneous coronary interventions (PCI), and what are the PCI procedural volumes in major markets, including India and China? -Who are the biotechnology companies developing advanced proprietary technologies and what are the trends in this market? -Which new chemical entities are currently in pre-clinical trials for principle disease areas such as Angina, Atherosclerosis, Arrhythmiasis, Atrial Fibrillation, Congestive Heart Failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. , Hypercholesterolemia, Hypertension, Myocardial myocardial /myo·car·di·al/ (-kahr´de-al) pertaining to the muscular tissue of the heart. myocardial pertaining to the muscular tissue of the heart (the myocardium). Infraction Violation or infringement; breach of a statute, contract, or obligation. The term infraction is frequently used in reference to the violation of a particular statute for which the penalty is minor, such as a parking infraction. INFRACTION. , and Thrombosis? -To what extent will the introduction of both bioabsorbable and drugeluting stents (DES) stents influence the coronary stent market? -Which new and emerging drugs will have the largest market impact, and when will they be launched? Content Outline: Executive Summary The Management of Cardiovascular Disease Cardiovascular and Interventional Procedures Emerging Coronary Stents and Stent Systems Innovations in Minimally Invasive Cardiac Surgery Cardiovascular Drugs in Early Stage Development New and Emerging Cardiovascular Drugs Chapter 1 The Management of Cardiovascular Disease Chapter 2 Latest Developments in Cardiovascular and PCI Procedures Chapter 3 Emerging Coronary Stents and Stent Systems Chapter 4 Innovations in Minimally Invasive Cardiac Surgery (MICS) Chapter 5 Cardiovascular Drugs in Early Stage Development Chapter 6 New and Emerging Cardiovascular Drugs Chapter 7 Appendix Glossary Index List of Figures List of Tables Companies Mentioned: - Cordis (Johnson & Johnson) - Boston Scientific Corporation - Medtronic and Abbot Laboratories (Abbott Vascular) For more information visit http://www.researchandmarkets.com/reports/c69221 Source: Business Insights |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion